Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5821-5830

  Zhao, Yingshe ^a,c   Bachelier, Richard ^a,c   Treilleux, Isabelle ^b   Pujuguet, Philippe ^d   Peyruchaud, Olivier ^a,c   Baron, Roland ^e   Clément Lacroix, Philippe ^d   Clézardin, Philippe ^a,c  

^a INSERM   (France)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITÉ LYON 1   (France)

^d Galapagos   (France)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA V BETA 3 INTEGRIN; BETA3 INTEGRIN; CD51 ANTIGEN; GREEN FLUORESCENT PROTEIN; INTEGRIN; PSK 1404; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DESTRUCTION; BONE MARROW; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER CELL; CELL INVASION; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOCLAST; OSTEOLYSIS; OVARY CANCER; PRIORITY JOURNAL; TIBIA; TUMOR CELL; TUMOR VOLUME; ANIMAL; BREAST TUMOR; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; METASTASIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 34250865694     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4499     Document Type: Article

References (32)

1. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005;12:549-83.
2. 3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A 2003;100:14205-10.
3. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
4. Bendre SM, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002;62:5571-9.
5. Hiraga T, Myyoui A, Choi ME, Yoshikawa H, Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-β enhances bone metastases in breast cancer. Cancer Res 2006;66:2067-73.
6. Boucharaba A, Serre CM, Grès S, et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004;114:1714-25.
7. Guo W, Giancotti FG. Integrin signalling during tumor progression. Nat Rev Mol Cell Biol 2004;5:816-26.
8. 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res 2006;66:8648-54.
9. 3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002;16:1266-8.
10. 3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 2006;8:R20; doi:10.1186/bcr1398.
11. 3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 2004;96:956-65.
12. Waltregny D, Bellahcène A, De Leval X, Florkin B, Weidle U, Castronovo V. Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 2000;15:834-43.
13. 3 expression by bone-residing breast cancer metastasis. Diagn Mol Pathol 1996;5:127-35.
14. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
15. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997;99:2284-92.
16. Hartman GD, Duggan ME. α(v)β(3) Integrin antagonists as inhibitors of bone resorption. Expert Opin Investig Drugs 2000;9:1281-91.
17. 3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 2003;20:413-20.
18. 3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis 2004;21:119-28.
19. Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Min Res 2001;16:2027-34.
20. Peyruchaud O, Nurden AT, Milet S, et al. R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of integrin IIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome. Blood 1998;92:4178-87.
21. 3 Antagonists based on a central thiophene scaffold. Bioorg Med Chem Lett 2001;11:2011-5.
22. Chico TJ, Chamberlain J, Gunn J. Effect of selective or combined inhibition of integrins α(IIb)β(3) and α(v)β(3) on thrombosis and neointima after oversized porcine coronary angioplasty. Circulation 2001;10:1135-41.
23. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
24. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:696-6.
25. Bandyopadhyay A, Agyin JK, Wang L, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res 2006;66:6714-21.
26. 3 integrins by SDF-1/CXCL12 increases the aggressiveness of prostate cancer cells. Prostate 2007;67:61-73.
27. 3 integrin promoter in osteoclast differentiation. Gene 2006;372:92-102.
28. van der Pluijm G, Vloedgraven H, Papapoulos S, et al. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest 1997;77:665-75.
29. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98:1853-8.
30. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
31. Clézardin P, Ebetino FH, Fournier PGJ. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4.
32. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001;13:563-8.